Uncategorized

Allorion Therapeutics (“Allorion”), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B financing round.

InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China.

Released Thursday, the budget also proposes to extend Medicare solvency and give the federal government more power to negotiate prescription drug prices.

COVID-19 stayed as the third top telehealth diagnosis nationally and accounted for a larger share of claims in December, Fair Health found.

Despite missing the initial mark, new analysis of Clene’s gold nanocrystal therapy from the HEALEY ALS trial indicates the asset still shows promise.

Titan’s robotic surgery device faced delays in development that forced the firm to put off a planned FDA submission. The company has laid off its technical staff as it seeks to sell its assets.

California Gov. Gavin Newsom is making good on his threat to no longer do business with Walgreens over abortion pill access, illustrating how the drugstore industry is attempting to navigate shifting state abortion laws.

Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.

Can ChatGPT help you find a new job in an industry as complex as the life sciences? BioSpace’s career editor decided to put it to the test – here’s what she discovered. 

AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.